Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Aug 1, 2024 – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss ...

In this episode, Riggs highlights Oncocyte's innovative strategies in molecular diagnostic technology and the significant impact of this technology on patient care. Hosted by Tom Hickey, a partner at Excelerant Consulting and a seasoned expert in medical device commercialization, the episode delves into Riggs' journey at Oncocyte, from his start as Senior Director of Business Development and General Manager of the Transplant Division to his leadership as CEO. The discussion also explores his entrepreneurial ...

DisclaimerThis communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients' securities. See www.pcgadvisory.com/disclosures. Under the leadership of CE ...

Oncocyte Appoints Andrea James as Chief Financial Officer "We are thrilled to welcome Andrea as we approach the inflection point of commercial launch," Oncocyte CEO Josh Riggs said. "She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team. "We expect 2024 and 2025 ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (NASDAQ:OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new clinical uses for VitaGraft Kidney, including thera ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new clinical uses for VitaGraft Kidney, including ther ...

Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte's Drs. Ekke Schuetz and Julia Bec ...

Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte's Drs. Ekke Schuetz and Julia Bec ...

财务数据和关键指标变化 - 公司第一季度净收入为176,000美元,较2023年同期下降41%,主要是由于公司在产品开发和商业化方面的战略投资 [26][27] - 研发费用增加2%,反映了公司对创新的承诺和开发套装产品的重点 [26] - 销售和营销费用增加22%,主要由于销售和商业化活动的加强 [26] - 一般和行政费用下降22%,主要是由于股票激励和人员成本的减少,反映了公司持续的精简运营和提高财务效率的举措 [26][27] 各条业务线数据和关键指标变化 - 公司在移植监测业务方面取得重大进展,与Bio-Rad Laboratories的合作是一个重要里程碑 [6] - 公司的移植监测产品GraftAssure RUO预计将于第二季度开始发货,并在第四季度和2025年开始产生收入 [36] - 公司的肿瘤诊断产品DetermaIO和DetermaCNI也在取得进展,预计2024年将有相关论文发表,支持临床应用和获得报销 [23] 各个市场数据和关键指标变化 - 公司正在积极拓展欧洲和全球市场,目前全球移植市场年增长率为9.1%,但大部分收入集中在美国中央实验室模式 [13][14] - 公司计划在美国和欧盟启动200多个潜在的移植中心,每个中心的经常性试剂收入预计可达百万美元 [17][20] 公司战略和发展方向及行业竞争 - 公司正在向监管套装产品过渡,预计将在2025年底前获得FDA批准 [29][30] - 公司的移植监测技术基于SNP检测,在检测速度、易用性和经济性方面具有优势 [19][20] - 公司正在与研究机构合作,支持新的临床应用研究,以推动产品的采用和未来发展 [11][12] 管理层对经营环境和未来前景的评论 - 公司预计未来12-18个月将是公司发展的关键时期,将执行多项里程碑,推动各业务的价值创造 [5] - 公司看好移植监测市场的增长前景,认为监管套装产品将主导未来市场 [13][15] - 公司在肿瘤诊断业务也有重大发展机会,DetermaIO和DetermaCNI两个产品市场空间广阔 [23] - 公司有信心通过战略合作、创新产品和精简运营,实现持续增长和盈利 [30][31] 问答环节重要的提问和回答 问题1 **Mike Matson 提问** GraftAssure研究产品今年是否会有重大销售 [35] **Josh Riggs 回答** 预计第二季度开始发货给首批客户,第四季度和2025年开始产生收入 [36] 问题2 **Mason Carrico 提问** 公司如何看待临床医生从现有移植监测产品转向公司产品 [41] **Josh Riggs 回答** 转换过程不会一蹴而就,需要建立信任,但医院内部使用自有产品的动力很强,尤其是监管产品上市后 [42][43] 问题3 **Mason Carrico 提问** 公司正在招聘的商业团队进展如何 [46] **Josh Riggs 回答** 计划在本季度底前完成招聘,并在第三季度进行培训,以便在第四季度投入市场 [47]

Recent Highlights "In the first quarter of 2024, Oncocyte made significant progress toward commercializing its innovative blood-based diagnostic tests. That progress was bolstered by a $15.8 million equity private placement and a global strategic partnership with Bio-Rad Laboratories," said Josh Riggs, Oncocyte's CEO. "We believe that the collaboration with Bio-Rad is pivotal for the upcoming launch of our GraftAssure RUO transplant rejection diagnostic test kit and central to our mission of developing and ...